N-salicyloyl-β-alanine | 6292-94-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-salicyloyl-β-alanine
• 英文别名: N-salicyloyl-β-alanine；N-Salicyloyl-β-alanin；3-Salicyloylamino-propionsaeure；3-[(2-Hydroxybenzoyl)amino]propanoic acid
• CAS: 6292-94-0
• 化学式: C₁₀H₁₁NO₄
• mdl: MFCD09047510
• 分子量: 209.202
• InChiKey: QFHIOEUDLWISBO-UHFFFAOYSA-N

物化性质

• 熔点：
  152-153 °C
• 沸点：
  493.7±30.0 °C(Predicted)
• 密度：
  1.342±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  86.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-salicyloyl-β-alanine 在 水 、 selenium tetrachloride 作用下， 以 四氢呋喃 为溶剂， 反应 25.0h， 生成 3-(2-hydroxy-5-seleninobenzamido)propanoic acid
  参考文献：
  名称：

  取代的水杨基-5-硒酸的疏水性和谷胱甘肽过氧化物酶活性：基于芳香族硒化合物的疏水性重新研究

  摘要：

  先前我们已经表明，一些5-硒化水杨酸衍生物表现出的谷胱甘肽过氧化物酶（GPx）样活性高于或等于依伯硒仑[Yu et al。，Chem。欧元。J.，2008，14，7066; 单位 生物分子 化学 ，2010，8，828]。为了解不存在具有loger侧链的水杨酰甘氨酸5-硒酸酐的同系物没有GPx样活性的情况，我们进一步合成了19种新衍生物（甲基或苯基水杨酸酯的5-硒酸，N-水杨酰ω-羧烷基胺或ñ-水杨酰基烷基/苯基胺，及其一些二硒化物）。某些带有长侧链或环己基的5-硒酸，无论其衍生自ω-羧烷基胺还是简单的烷基胺，都没有GPx样的活性。缺乏类似GPx的活性，使我们可以定量地将上述3个系列同源物的GPx活性与其疏水性（ClogP）相关联，在每个系列中均显示出令人满意的相关性。然后将分子疏水性广泛应用于包括二芳基二硒化物和依布硒仑衍生物在内的各种已知的芳香族硒GPx模拟物，以相对定量的方式解释其G

  DOI：

  10.1016/j.jorganchem.2018.02.045
• 作为产物：
  描述：

  3-(2-acetoxybenzamido)propanoic acid 在 sodium hydroxide 作用下， 反应 2.0h， 生成 N-salicyloyl-β-alanine
  参考文献：
  名称：

  Synthesis and Evaluation of Compounds That Facilitate the Gastrointestinal Absorption of Heparin

  摘要：

  A family of novel compounds (delivery agents) that promote the gastrointestinal absorption of USP heparin in rats and primates has been discovered. The delivery agents in combination with heparin were administered either orally or intracolonically in an aqueous propylene glycol solution and caused dramatic increases in both plasma heparin concentrations (anti-Factor Xa) and clotting times (APTT). Using one of the most effective delivery agents in this series, an estimated relative bioavailability of 8% can be achieved following oral administration to cynomolgus monkeys. To establish a correlation between the in vivo data and an in vitro parameter, immobilized artificial membrane (IAM) chromatography was performed. Log relative k' values were correlated to the efficiency of oral heparin delivery.

  DOI：

  10.1021/jm970811m

文献信息

• WRINKLE-IMPROVING AGENT
  申请人：Shiseido Company, Limited

  公开号：EP1941861A1

  公开（公告）日：2008-07-09

  The invention provides a novel wrinkle-improving agent that has an effect of improving wrinkles, that does not entail problems of safety or pain even when applied to the skin, and that contains a very safe substance as an active component. A discovery was made that N-benzoyl-β-alanine, other specific β-alanine derivatives, and salts thereof have a wrinkle-improving effect, whereby a wrinkle-improving agent containing as an active component one, two, or more types of compounds selected from the group composed of these specific β-alanine derivatives and the salts thereof was developed.

  该发明提供了一种新型的改善皱纹的剂，具有改善皱纹的效果，即使应用于皮肤也不会带来安全或疼痛问题，并且包含一种非常安全的物质作为活性成分。发现N-苯甲酰-β-丙氨酸、其他特定的β-丙氨酸衍生物及其盐具有改善皱纹的效果，因此开发了一种改善皱纹的剂，其活性成分包含从这些特定的β-丙氨酸衍生物及其盐组成的群体中选择的一种、两种或更多种化合物。
• Oral GLP-1 Formulations
  申请人：Sarubbi Donald J.

  公开号：US20100016229A1

  公开（公告）日：2010-01-21

  The present invention provides pharmaceutical compositions comprising of at least one delivery agent and GLP-1. These pharmaceutical compositions facilitate the oral delivery of GLP-1, providing improved (e.g. increased) bioavailability of GLP-1 compared to administration of GLP-1 without a delivery agent.

  本发明提供了包含至少一种传递剂和GLP-1的药物组合物。这些药物组合物促进了GLP-1的口服给药，相比于没有传递剂的GLP-1给药，提高了GLP-1的生物利用度（例如，增加了生物利用度）。
• Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin
  申请人：Kaminuma Mikiko

  公开号：US20120232111A1

  公开（公告）日：2012-09-13

  The invention provides a parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/ameliorating agent that has a function such as parakeratosis inhibition, pore shrinkage, or rough skin—inhibition/abatement, poses no safety problems such as sensory irritation, and is very safe, and further provides an external composition for skin to which a compound having the above-mentioned function has been added. The parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/ameliorating agent comprises one or more compounds selected from the group consisting of β-alanine derivatives and salts thereof. The external composition for skin comprises the one or more compounds selected from the group consisting of β-alanine derivatives and salts thereof as the above-mentioned parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/ameliorating agent.

  本发明提供了一种角化过度抑制剂、毛孔收缩剂或粗糙肌肤预防/改善剂，具有诸如角化过度抑制、毛孔收缩或粗糙肌肤抑制/减轻等功能，不会引起感觉刺激等安全问题，非常安全，还提供了一种外用皮肤组成物，其中添加了具有上述功能的化合物。该角化过度抑制剂、毛孔收缩剂或粗糙肌肤预防/改善剂包括从β-丙氨酸衍生物和其盐的群组中选择的一种或多种化合物。该外用皮肤组成物包括上述β-丙氨酸衍生物和其盐中的一种或多种作为上述角化过度抑制剂、毛孔收缩剂或粗糙肌肤预防/改善剂。
• PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN
  申请人：Shiseido Company, Limited

  公开号：EP1880711A1

  公开（公告）日：2008-01-23

  The invention provides a parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/amaliorating agent that has a function such as parakeratosis inhibition, pore shrinkage, or rough skin -inhibition/abatement, poses no safety problems such as sensory irritation, and is very safe, and further provides an external composition for skin to which a compound having the above-mentioned function has been added. The parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/amaliorating agent comprises one or more compounds selected from the group consisting of β-alanine derivatives and salts thereof. The external composition for skin comprises the one or more compounds selected from the group consisting of β-alanine derivatives and salts thereof as the above-mentioned parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/amaliorating agent.

  本发明提供了一种角化抑制剂、毛孔收缩剂或皮肤粗糙预防/改善剂，它具有抑制角化、收缩毛孔或皮肤粗糙抑制/改善等功能，不会造成感官刺激等安全问题，而且非常安全，并进一步提供了一种添加了具有上述功能的化合物的皮肤外用组合物。角化抑制剂、毛孔收缩剂或皮肤粗糙预防/改善剂包括一种或多种选自 β-丙氨酸衍生物及其盐类的化合物。皮肤外用组合物包括选自由 β-丙氨酸衍生物及其盐组成的组的一种或多种化合物，作为上述角化病抑制剂、毛孔收缩剂或皮肤粗糙预防/改善剂。
• Mukherjee, G. N.; Sarkar, S., Indian Journal of Chemistry, Section A: Inorganic, Physical, Theoretical and Analytical, 1988, vol. 27, # 6, p. 514 - 518
  作者：Mukherjee, G. N.、Sarkar, S.

  DOI：——

  日期：——